Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sephin1
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inflectis Bioscience
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : IFB-088 is entering Phase 2 clinical trials for the treatment of ALS and CMT and has shown encouraging preclinical results for the treatment of multiple sclerosis (MS).
Product Name : IFB-088
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 22, 2021
Lead Product(s) : Sephin1
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inflectis Bioscience
Deal Size : Undisclosed
Deal Type : Licensing Agreement